Does Diabetes Influence Adherence in Glaucoma Patients?

Abstract

With chronic diseases, patient adherence plays a crucial role in delaying disease progression and in determining the success of therapy. Problems arise not only from low medication adherence, but also non-adherence to recommended follow-up examinations. Obtaining an accurate estimate of adherence is difficult, especially in glaucoma patients, due to the fact that most antihypertensive drugs are administered in the form of eye drops. There is great variability in the published adherence values for glaucoma patients. Most studies report an average medication adherence of approximately 70%, with around 50% of patients having good adherence (at least 80% of medication administered as planned). Furthermore, 6.8 – 31.4% of the eye drops do not end up in the patientʼs eye, which means there is even less active ingredient to achieve a therapeutic effect. Glaucoma patients also show low persistence and adherence to follow-up appointments. Since diabetes increases the risk for POAG and secondary glaucoma and given that diabetics have particularly low adherence, the question arose whether a diabetes diagnosis is associated with reduced adherence in glaucoma patients. Previous studies found no significant association between diabetes and reduced adherence in glaucoma patients, although a significant impact of elevated HbA_1c on adherence in glaucoma patients was found in one study. However, this connection still needs to be examined more closely in studies with larger samples.

Key words

adherence - compliance - persistence - glaucoma - diabetes

Publication History

Received: 20 August 2022

Accepted: 08 November 2022

Accepted Manuscript online:
09 November 2022

Article published online:
12 January 2023

• References/Literatur

• 1 Quartilho A, Simkiss P, Zekite A. et al. Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013. Eye (Lond) 2016; 30: 602-607
• 2 Tham YC, Li X, Wong TY. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121: 2081-2090
• 3 Schuster AK, Erb C, Hoffmann EM. et al. The Diagnosis and Treatment of Glaucoma. Dtsch Arztebl Int 2020; 117: 225-234
• 4 Hoevenaars JG, Schouten JS, van den Borne B. et al. Will improvement of knowledge lead to improvement of compliance with glaucoma medication?. Acta Ophthalmologica 2008; 86: 849-855
• 5 Cramer JA, Roy A, Burrell A. et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-47
• 6 Zaharia AC, Dumitrescu OM, Radu M. et al. Adherence to Therapy in Glaucoma Treatment–A Review. J Pers Med 2022; 12: 514
• 7 Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497
• 8 Sayner R, Carpenter DM, Blalock SJ. et al. Accuracy of Patient-reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared With Electronic Monitors. Clin Ther 2015; 37: 1975-1985
• 9 Friedman DS, Quigley HA, Gelb L. et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci 2007; 48: 5052-5057
• 10 De Amici D, Klersy C, Ramajoli F. et al. Impact of the Hawthorne Effect in a Longitudinal Clinical Study: The Case of Anesthesia. Control Clin Trials 2000; 21: 103-114
• 11 Newman-Casey PA, Niziol LM, Gillespie BW. et al. The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 2020; 127: 477-483
• 12 Guven S, Koylu MT, Mumcuoglu T. Adherence to glaucoma medication, illness perceptions, and beliefs about glaucoma: Attitudinal perspectives among Turkish population. Eur J Ophthalmol 2021; 31: 469-476
• 13 Newman-Casey PA, Robin AL, Blachley T. et al. The Most Common Barriers to Glaucoma Medication Adherence: A Cross-Sectional Survey. Ophthalmology 2015; 122: 1308-1316
• 14 Ung C, Zhang E, Alfaro T. et al. Glaucoma severity and medication adherence in a county hospital population. Ophthalmology 2013; 120: 1150-1157
• 15 Shu YH, Wu J, Luong T. et al. Topical Medication Adherence and Visual Field Progression in Open-angle Glaucoma: Analysis of a Large US Health Care System. J Glaucoma 2021; 30: 1047-1055
• 16 Shirai C, Matsuoka N, Nakazawa T. Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: a retrospective non-interventional cohort study. BMC Ophthalmol 2021; 21: 52
• 17 Newman-Casey PA, Weizer JS, Heisler M. et al. Systematic review of educational interventions to improve glaucoma medication adherence. Semin Ophthalmol 2013; 28: 191-201
• 18 Jang Y, Jee D, Lee D. et al. Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data. Int J Environ Res Public Health 2021; 18: 4106
• 19 Newman-Casey PA, Dayno M, Robin AL. Systematic Review of Educational Interventions to Improve Glaucoma Medication Adherence: an update in 2015. Expert Rev Ophthalmol 2016; 11: 5-20
• 20 Okeke CO, Quigley HA, Jampel HD. et al. Adherence with Topical Glaucoma Medication Monitored Electronically: The Travatan Dosing Aid Study. Ophthalmology 2009; 116: 191-199
• 21 Cate H, Bhattacharya D, Clark A. et al. Patterns of adherence behaviour for patients with glaucoma. Eye (Lond) 2013; 27: 545-553
• 22 Cate H, Bhattacharya D, Clark A. et al. Improving adherence to glaucoma medication: a randomised controlled trial of a patient-centred intervention (The Norwich Adherence Glaucoma Study). BMC Ophthalmol 2014; 14: 32
• 23 Frech S, Kreft D, Guthoff RF. et al. Pharmacoepidemiological assessment of adherence and influencing co-factors among primary open-angle glaucoma patients-An observational cohort study. PLoS One 2018; 13: e0191185
• 24 Tatham AJ, Sarodia U, Gatrad F. et al. Eye drop instillation technique in patients with glaucoma. Eye (Lond) 2013; 27: 1293-1298
• 25 Gupta R, Patil B, Shah BM. et al. Evaluating eye drop instillation technique in glaucoma patients. J Glaucoma 2012; 21: 189-192
• 26 Stone JL, Robin AL, Novack GD. et al. An objective evaluation of eyedrop instillation in patients with glaucoma. Arch Ophthalmol 2009; 127: 732-736
• 27 Nordstrom BL, Friedman DS, Mozaffari E. et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005; 140: 598-606
• 28 Newman-Casey PA, Blachley T, Lee PP. et al. Patterns of Glaucoma Medication Adherence over Four Years of Follow-Up. Ophthalmology 2015; 122: 2010-2021
• 29 Sleath B, Blalock SJ, Carpenter DM. et al. Ophthalmologist-patient communication, self-efficacy, and glaucoma medication adherence. Ophthalmology 2015; 122: 748-754
• 30 Cohen Castel O, Keinan-Boker L, Geyer O. et al. Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting. Fam Pract 2014; 31: 453-461
• 31 Salman M, Andrews C, Heisler M. et al. Psychosocial Predictors of Glaucoma Medication Adherence Among the Support, Educate, Empower (SEE) Personalized Glaucoma Coaching Pilot Study Participants. Am J Ophthalmol 2020; 216: 207-218
• 32 Ung C, Murakami Y, Zhang E. et al. The association between compliance with recommended follow-up and glaucomatous disease severity in a county hospital population. Am J Ophthalmol 2013; 156: 362-369
• 33 Zhao YX, Chen XW. Diabetes and risk of glaucoma: systematic review and a Meta-analysis of prospective cohort studies. Int J Ophthalmol 2017; 10: 1430-1435
• 34 Song BJ, Aiello LP, Pasquale LR. Presence and Risk Factors for Glaucoma in Patients with Diabetes. Curr Diab Rep 2016; 16: 124
• 35 Barac IR, Pop MD, Gheorghe AI. et al. Neovascular secondary glaucoma, etiology and pathogenesis. Rom J Ophthalmol 2015; 59: 24-28
• 36 Shen L, Walter S, Melles RB. et al. Diabetes Pathology and Risk of Primary Open-Angle Glaucoma: Evaluating Causal Mechanisms by Using Genetic Information. Am J Epidemiol 2016; 183: 147-155
• 37 Halilovic EA, Ljaljevic S, Alimanovic I. et al. Analysis of the influence of type of diabetes mellitus on the development and type of glaucoma. Med Arch 2015; 69: 34-37
• 38 Rolnick SJ, Pawloski PA, Hedblom BD. et al. Patient characteristics associated with medication adherence. Clin Med Res 2013; 11: 54-65
• 39 Rozenfeld Y, Hunt JS, Plauschinat C. et al. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008; 14: 71-75
• 40 Cramer JA. A Systematic Review of Adherence With Medications for Diabetes. Diabetes Care 2004; 27: 1218-1224
• 41 Karter AJ, Parker MM, Moffet HH. et al. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res 2009; 44: 1640-1661
• 42 Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 2011; 65: 314-322
• 43 Sloan FA, Brown DS, Carlisle ES. et al. Monitoring visual status: why patients do or do not comply with practice guidelines. Health Serv Res 2004; 39: 1429-1448
• 44 Cougnard-Grégoire A, Korobelnik JF, Delyfer MN. et al. Trends in the Use of Eye Care Services in Adults Treated for Diabetes between 2008 and 2017 in France: A Nationwide Study. Ophthalmic Res 2020; 63: 452-459